Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET/CT on the clinical staging (TNM staging) of MTC.
Patients of either gender, aged ≥ 18 years and ≤80 years.
Patients with pathologic findings confirming the diagnosis of MTC
Patients with MTC recurrence
Signed written consent
Pregnant or breastfeeding female patients
Patients with claustrophobic behavior
The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Single group
68Ga-MGS5
DrugEach patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
SUVmax and SUVpeak
Determination of SUVmean and SUVpeak for detected lesions and discernible organs of 68Ga-MGS5 and 68Ga-DOTATATE scan.
immunohistochemistry
Primary and lymph node metastases were stained with CCK2 immunohistochemistry and scored.
Click on the lead sponsor to view all of their trials.
